Ga-prostate-specific membrane antigen (PSMA) PET/CT is increasingly used to evaluate recurrent prostatic malignancy due to its high specificity. A 56-year-old man with previous history of treated prostate cancer 4 years earlier presented with rising prostate-specific antigen level and underwent Ga-PSMA PET/CT, which demonstrated an enlarging pulmonary nodule without PSMA avidity. The pulmonary nodule, however, showed moderate uptake on a corresponding FDG PET/CT study, suspicious of primary lung malignancy. Cytological and histopathological examination of the pulmonary nodule confirmed a metastatic deposit from ductal prostatic adenocarcinoma, an uncommon variant of prostatic malignancy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000001329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of the Forkhead box family protein FOXF2 in the progression of solid tumor: systematic review.
J Cancer Res Clin Oncol
December 2024
Department of Thoracic Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong, 518036, China.
Background: FOXF2 was reported to involve in a variety of biological behaviors that include the development of the central nervous system, tissue homeostasis, epithelia-mesenchymal interactions, regulation of embryonic development, and organogenesis.
Purpose: Understanding how FOXF2 influences the growth and development of cancer could provide valuable insights for researchers to develop novel therapeutic strategies.
Results: In this review, we investigate the underlying impact of FOXF2 on tumor cells, including the transformation of cellular phenotype, capacity for migration, invasion, and proliferation, colonization of circulating cells, and formation of metastatic nodules.
Octreotide plus IBI-318 plus anlotinib in the treatment of multiple neuroendocrine metastases of unknown primary lesions: a case report.
Front Oncol
December 2024
Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, China.
Background: The second-line treatment of neuroendocrine tumors (NETs) of unknown primary origin remains uncertain. This report presented a patient who received octreotide plus IBI-318 plus anlotinib as a second-line treatment for multiple metastatic NETs of unknown primary lesions after the failure of octreotide plus everolimus.
Case Presentation: A 32-year-old male patient presented with elevated CEA (197.
[A Case of Breast Cancer Recurrence 32 Years after Primary Surgery].
Gan To Kagaku Ryoho
December 2024
Dept. of Surgery, Kikkoman General Hospital.
An 80-year-old woman presented with blood-stained sputum. Computed tomography revealed the presence of multiple lung nodules. The patient underwent surgery for left breast cancer at 48 years of age.
View Article and Find Full Text PDFThyroid metastasis of clear renal cell carcinoma: a case report and review of the literature.
Pan Afr Med J
December 2024
Endocrinology and Nutrition Department, Hospital General Universitario Santa Lucía, Murcia, Spain.
The thyroid is a rare site for finding tumor metastases. Renal, colorectal, pulmonary, and mammary origin are the most frequent primary neoplasms. Clinical suspicion, early diagnosis, and active surveillance are important during follow-up.
View Article and Find Full Text PDFComputer Assisted Nodule Analysis and Risk Yield is Associated With Occult Lymph Node Status in Clinical Stage I-IIA Lung Adenocarcinoma Undergoing Resection.
Clin Lung Cancer
December 2024
Department of Surgery, Thoracic Surgery, INOVA Fairfax Medical Center, Fairfax, VA. Electronic address:
Background: Current staging work-up does not capture all occult lymph node (OLN) disease. We sought to determine if Computer Assisted Nodule Analysis and Risk Yield (CANARY) analysis could help distinguish OLN status in early-stage lung adenocarcinoma.
Methods: Retrospective review of resected lung cancer patients from 2016 to 2021 was performed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!